Gbola Amusa
Stock Analyst at Chardan Capital
(1.94)
# 2,948
Out of 4,711 analysts
61
Total ratings
40%
Success rate
2.87%
Average return
Main Sectors:
Stocks Rated by Gbola Amusa
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADVM Adverum Biotechnologies | Downgrades: Neutral | $200 → $50 | $4.74 | +954.85% | 2 | Apr 29, 2021 | |
| TSHA Taysha Gene Therapies | Maintains: Buy | $60 → $68 | $1.85 | +3,548.65% | 3 | Apr 13, 2021 | |
| FBRX Forte Biosciences | Maintains: Buy | $2,875 → $2,625 | $19.34 | +13,472.91% | 4 | Mar 17, 2021 | |
| SLDB Solid Biosciences | Maintains: Buy | $188 → $300 | $4.16 | +7,111.54% | 5 | Mar 16, 2021 | |
| PASG Passage Bio | Maintains: Buy | $36 → $45 | $0.66 | +6,718.18% | 3 | Mar 8, 2021 | |
| MCRB Seres Therapeutics | Upgrades: Buy | $28 → $30 | $0.92 | +3,176.90% | 2 | Mar 5, 2021 | |
| QURE uniQure | Maintains: Buy | $85 → $100 | $16.98 | +488.93% | 4 | Mar 2, 2021 | |
| SYBX Synlogic | Maintains: Buy | $75 → $150 | $1.42 | +10,463.38% | 2 | Jan 13, 2021 | |
| IOVA Iovance Biotherapeutics | Maintains: Buy | $53 → $50 | $7.38 | +577.51% | 3 | Oct 6, 2020 | |
| IMVT Immunovant | Maintains: Buy | $35 → $45 | $25.86 | +74.01% | 3 | Aug 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $100 → $115 | $164.83 | -30.23% | 2 | Aug 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $73 → $100 | $40.72 | +145.58% | 1 | Jul 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $95 | $39.39 | +141.18% | 2 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $19 → $15 | $9.80 | +53.06% | 4 | Aug 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $130 | $7.62 | +1,606.04% | 4 | Jul 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $100 | $2.19 | +4,466.21% | 6 | Mar 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $2.5 → $2 | $631.69 | -99.68% | 2 | Jan 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $5.61 | - | 3 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $300 → $350 | $701.85 | -50.13% | 6 | Dec 12, 2016 |
Adverum Biotechnologies
Apr 29, 2021
Downgrades: Neutral
Price Target: $200 → $50
Current: $4.74
Upside: +954.85%
Taysha Gene Therapies
Apr 13, 2021
Maintains: Buy
Price Target: $60 → $68
Current: $1.85
Upside: +3,548.65%
Forte Biosciences
Mar 17, 2021
Maintains: Buy
Price Target: $2,875 → $2,625
Current: $19.34
Upside: +13,472.91%
Solid Biosciences
Mar 16, 2021
Maintains: Buy
Price Target: $188 → $300
Current: $4.16
Upside: +7,111.54%
Passage Bio
Mar 8, 2021
Maintains: Buy
Price Target: $36 → $45
Current: $0.66
Upside: +6,718.18%
Seres Therapeutics
Mar 5, 2021
Upgrades: Buy
Price Target: $28 → $30
Current: $0.92
Upside: +3,176.90%
uniQure
Mar 2, 2021
Maintains: Buy
Price Target: $85 → $100
Current: $16.98
Upside: +488.93%
Synlogic
Jan 13, 2021
Maintains: Buy
Price Target: $75 → $150
Current: $1.42
Upside: +10,463.38%
Iovance Biotherapeutics
Oct 6, 2020
Maintains: Buy
Price Target: $53 → $50
Current: $7.38
Upside: +577.51%
Immunovant
Aug 25, 2020
Maintains: Buy
Price Target: $35 → $45
Current: $25.86
Upside: +74.01%
Aug 19, 2020
Maintains: Buy
Price Target: $100 → $115
Current: $164.83
Upside: -30.23%
Jul 28, 2020
Maintains: Buy
Price Target: $73 → $100
Current: $40.72
Upside: +145.58%
Jul 15, 2020
Maintains: Buy
Price Target: $84 → $95
Current: $39.39
Upside: +141.18%
Aug 17, 2018
Downgrades: Neutral
Price Target: $19 → $15
Current: $9.80
Upside: +53.06%
Jul 16, 2018
Maintains: Buy
Price Target: $90 → $130
Current: $7.62
Upside: +1,606.04%
Mar 27, 2018
Maintains: Neutral
Price Target: $75 → $100
Current: $2.19
Upside: +4,466.21%
Jan 10, 2018
Upgrades: Neutral
Price Target: $2.5 → $2
Current: $631.69
Upside: -99.68%
Nov 10, 2017
Upgrades: Buy
Price Target: n/a
Current: $5.61
Upside: -
Dec 12, 2016
Upgrades: Neutral
Price Target: $300 → $350
Current: $701.85
Upside: -50.13%